Entera Bio (NASDAQ:ENTX) Shares Up 6%

Shares of Entera Bio Ltd. (NASDAQ:ENTXGet Free Report) rose 6% on Monday . The company traded as high as $1.77 and last traded at $1.77. Approximately 47,530 shares were traded during trading, a decline of 72% from the average daily volume of 172,747 shares. The stock had previously closed at $1.67.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a report on Wednesday, June 5th.

Check Out Our Latest Report on Entera Bio

Entera Bio Price Performance

The company has a market capitalization of $64.40 million, a PE ratio of -6.43 and a beta of 1.60. The company has a 50-day moving average of $2.14 and a two-hundred day moving average of $1.61.

Entera Bio (NASDAQ:ENTXGet Free Report) last released its earnings results on Friday, May 10th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, research analysts anticipate that Entera Bio Ltd. will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC bought a new position in Entera Bio Ltd. (NASDAQ:ENTXFree Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 22,040 shares of the company’s stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

Further Reading

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.